Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPH-035 Versus Ocrevus® in Relapsing-remitting or Secondary Progressive Multiple Sclerosis
NCT07597668Phase 1Active, not recruiting
- Sponsor
- R-Pharm
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RPH-035 in multiple sclerosis (MS) (2 arms), sponsored by R-Pharm. Primary endpoint: Area under the concentration-time pharmacokinetic curve of ocrelizumab. Started Apr 2025; status: active, not recruiting.
02
Drugs
RPH-035
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07597668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07597668.